🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 12 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 28/02/2020 | 215,57 | 224,54 | 215,50 | 224,03 | +0,33% | 4,19% | 2.485.900 |
| 27/02/2020 | 228,48 | 231,63 | 218,01 | 223,30 | -3,77% | 5,96% | 1.973.000 |
| 26/02/2020 | 232,41 | 237,37 | 229,49 | 232,04 | +0,89% | 3,39% | 1.578.500 |
| 25/02/2020 | 238,18 | 239,99 | 228,50 | 230,00 | -2,96% | 4,82% | 1.581.100 |
| 24/02/2020 | 241,44 | 242,76 | 235,70 | 237,01 | -3,77% | 2,92% | 1.659.300 |
| 21/02/2020 | 247,30 | 247,50 | 243,27 | 246,29 | +0,49% | 1,71% | 1.365.100 |
| 20/02/2020 | 247,29 | 247,70 | 242,59 | 245,10 | -1,08% | 2,07% | 1.524.800 |
| 19/02/2020 | 249,85 | 249,85 | 245,24 | 247,78 | +0,75% | 1,85% | 947.700 |
| 18/02/2020 | 244,92 | 246,00 | 241,09 | 245,93 | +0,87% | 2,00% | 1.305.400 |
| 14/02/2020 | 241,24 | 244,45 | 238,55 | 243,82 | +1,55% | 2,45% | 1.354.000 |
| 13/02/2020 | 241,41 | 245,39 | 239,73 | 240,09 | -0,88% | 2,34% | 1.329.200 |
| 12/02/2020 | 247,61 | 248,80 | 240,70 | 242,21 | -2,26% | 3,27% | 1.805.700 |
| 11/02/2020 | 245,00 | 249,00 | 242,78 | 247,81 | +1,25% | 2,54% | 2.280.000 |
| 10/02/2020 | 239,22 | 244,89 | 237,00 | 244,75 | +1,95% | 3,30% | 1.273.000 |
| 07/02/2020 | 237,66 | 240,34 | 234,10 | 240,06 | +0,39% | 2,63% | 1.443.100 |
| 06/02/2020 | 242,13 | 244,65 | 238,01 | 239,12 | -0,68% | 2,74% | 1.320.300 |
| 05/02/2020 | 241,61 | 244,41 | 240,00 | 240,76 | +0,46% | 1,83% | 1.951.600 |
| 04/02/2020 | 233,35 | 241,23 | 233,29 | 239,66 | +3,97% | 3,40% | 1.485.900 |
| 03/02/2020 | 230,76 | 233,78 | 225,01 | 230,51 | +1,52% | 3,80% | 1.988.000 |
| 31/01/2020 | 238,65 | 239,40 | 223,01 | 227,05 | -1,42% | 6,87% | 3.373.500 |
| 30/01/2020 | 230,84 | 231,75 | 228,68 | 230,31 | -0,90% | 1,33% | 1.169.500 |
| 29/01/2020 | 231,72 | 233,59 | 230,57 | 232,41 | +0,19% | 1,30% | 893.500 |
| 28/01/2020 | 228,53 | 232,30 | 227,57 | 231,97 | +2,02% | 2,07% | 861.800 |
| 27/01/2020 | 226,51 | 228,79 | 226,07 | 227,37 | -0,74% | 1,20% | 802.000 |
| 24/01/2020 | 234,07 | 235,18 | 228,42 | 229,06 | -2,07% | 2,89% | 904.300 |
| 23/01/2020 | 235,00 | 235,63 | 231,38 | 233,91 | -0,30% | 1,81% | 978.000 |
| 22/01/2020 | 234,94 | 237,47 | 234,40 | 234,61 | +0,26% | 1,31% | 1.134.000 |
| 21/01/2020 | 235,84 | 237,20 | 233,13 | 233,99 | -0,78% | 1,73% | 1.399.800 |
| 17/01/2020 | 236,51 | 236,51 | 232,82 | 235,83 | +0,14% | 1,56% | 1.599.300 |
| 16/01/2020 | 234,27 | 235,78 | 233,27 | 235,50 | +0,58% | 1,07% | 2.124.000 |